Humans have a close phylogenetic relationship with nonhuman primates (NHPs) and share
many physiological parallels, such as highly similar immune systems, with them. Importantly …

RV144 remains the only HIV-1 vaccine trial to demonstrate efficacy against HIV-1
acquisition. The prespecified analysis of immune correlates of risk showed that antibodies …

Antiretroviral drug therapy (ART) effectively suppresses replication of both the
immunodeficiency viruses, human (HIV) and simian (SIV); however, virus rebounds soon …

SARS-CoV-2 is considered a global emergency, resulting in an exacerbated crisis in the
health public in the world. Although there are advances in vaccine development, it is still …

A recombinant vaccine containing Aventis Pasteur's canarypox vector (ALVAC)–HIV and
gp120 alum decreased the risk of HIV acquisition in the RV144 vaccine trial. The substitution …

Background Avidity is defined as the strength of binding between immunoglobulin G (IgG)
and its specific target epitope. IgG of high avidity is established during affinity maturation …

Abstract The RV144 Thai trial HIV-1 vaccine of recombinant poxvirus (ALVAC) and
recombinant HIV-1 gp120 subtype B/subtype E (B/E) proteins demonstrated 31% vaccine …

Modifications to vaccine delivery that increase serum antibody longevity are of great interest
for maximizing efficacy. We have previously shown that a delayed fractional (DFx) dosing …

Animal and human data from various viral infections and vaccine studies suggest that
nonneutralizing antibodies (nNAb) without neutralizing activity in vitro may play an important …

Abstract Development of effective human immunodeficiency virus 1 (HIV-1) vaccines
requires synergy between innate and adaptive immune cells. Here we show that induction of …